5 Insightful Analyst Questions From Moderna’s Q3 Earnings Call

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
HubOpinion

Commentary: mRNA technology has cancer in its sights

With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough ...
Pulmonology Advisor

mRNA-1273 Vaccine Protective Against Severe COVID-19 Outcomes Across Seasons

Moderna's mRNA-1273 vaccine helped prevent medically attended COVID-19 and related hospitalizations across multiple respiratory seasons among adults.
American Association of Individual Investors

Which Is a Better Investment, Moderna, Inc. or Viridian Therapeutics, Inc. Stock?

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.